Solentim in the Press: “Fast-Tracking Cell-Line Development”, BioCompare
“Protein pharmaceuticals represent a multibillion-dollar market, but deciphering the most suitable biotherapeutic-producing cell lines is a substantial manufacturing bottleneck”, writes Lauren Tanabe for a recent article published by BioCompare.
CHO cells have been the expression system of choice for producing biological therapies for several decades; they are accepted by the FDA, easy to work with, and can express a range of proteins, amongst other benefits. However, in order to identify high-producing protein secreting clones, thousands of clones must be screened over many weeks, costing valuable time and money.
In this article, Ian Taylor, Chief Commercial Officer for Solentim, shares his expert insights on the efforts underway to streamline these processes and shorten cell-line development workflow timelines. Technologies such as ATUM’s Leap-In Transposase® are key to this, and can enable integration efficiency “several orders of magnitude higher than conventional cells”, rapidly generating stable cell lines, says Taylor. Researchers can also help single clones bounce back and develop into colonies by adding growth supplements such as Solentim’s InstiGRO animal competent-free supplement to cloning plates.
Dr Taylor also emphasises the importance of ensuring single-cell isolation and producing documentation of clonality for all cell line development work, and how instruments such as the VIPS can make this process routine and easy.
The article also shares insights from Susan Sharfstein, professor of nanobioscience at SUNY Polytechnic Institute, and Anne-Marie Zuurmond, director of biology at Charles River Laboratories, on how CRISPR is revolutionising cell-line development.
Read the full article here.